Brookline Capital Management Forecasts MRKR Q1 Earnings

Marker Therapeutics, Inc. (NASDAQ:MRKR) – Investment analysts at Brookline Capital Management issued their Q1 2025 EPS estimates for shares of Marker Therapeutics in a report issued on Monday, March 31st. Brookline Capital Management analyst L. Cann anticipates that the company will earn ($0.66) per share for the quarter. Brookline Capital Management currently has a “Strong-Buy” rating on the stock. The consensus estimate for Marker Therapeutics’ current full-year earnings is ($0.65) per share. Brookline Capital Management also issued estimates for Marker Therapeutics’ Q2 2025 earnings at ($0.77) EPS, Q3 2025 earnings at ($1.14) EPS, Q4 2025 earnings at ($1.80) EPS and FY2025 earnings at ($4.36) EPS.

Marker Therapeutics (NASDAQ:MRKR) last announced its quarterly earnings results on Monday, March 31st. The company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.14). The company had revenue of $1.22 million during the quarter, compared to analyst estimates of $5.25 million. Marker Therapeutics had a negative net margin of 179.74% and a negative return on equity of 89.63%.

MRKR has been the topic of a number of other reports. WBB Securities restated a “strong-buy” rating and issued a $12.50 price objective on shares of Marker Therapeutics in a report on Tuesday. Canaccord Genuity Group initiated coverage on shares of Marker Therapeutics in a report on Wednesday, March 5th. They issued a “buy” rating and a $8.00 price target on the stock.

Marker Therapeutics Trading Down 8.1 %

Shares of Marker Therapeutics stock opened at $1.01 on Thursday. The business’s fifty day moving average price is $1.52 and its 200 day moving average price is $2.68. Marker Therapeutics has a twelve month low of $1.00 and a twelve month high of $5.99. The stock has a market capitalization of $10.83 million, a P/E ratio of -0.84 and a beta of 1.54.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Millennium Management LLC acquired a new stake in shares of Marker Therapeutics in the fourth quarter valued at about $50,000. Invst LLC purchased a new position in Marker Therapeutics in the 3rd quarter worth approximately $56,000. Northern Trust Corp grew its position in Marker Therapeutics by 66.9% in the fourth quarter. Northern Trust Corp now owns 54,156 shares of the company’s stock valued at $168,000 after acquiring an additional 21,703 shares in the last quarter. LPL Financial LLC acquired a new stake in Marker Therapeutics in the fourth quarter valued at approximately $248,000. Finally, Aisling Capital Management LP raised its stake in shares of Marker Therapeutics by 3.5% during the fourth quarter. Aisling Capital Management LP now owns 325,370 shares of the company’s stock valued at $1,012,000 after purchasing an additional 11,084 shares during the period. 22.39% of the stock is owned by hedge funds and other institutional investors.

About Marker Therapeutics

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.